Report Summary

Market Performance:

On January 2, 2025, the pharmaceutical sector rose and fell by -2.22%, outperforming the CSI 300 Index by 0.69 pct, ranking 19th among the 31 sub-sectors of Shenwan. Among the pharmaceutical sub-industries, blood products (-0.67%), medical consumables (-1.94%), and medical equipment (-2.05%) performed first, while vaccines (-3.69%), hospitals (-2.65%), and in vitro diagnostics (-2.64%) performed last. In terms of individual stocks, the top 3 daily gainers are Shuangcheng Pharmaceutical (+9.98%), Kaikai Industrial (+8.80%), and Hehua (+6.62%); The top 3 decliners were SINBON Pharmaceutical (-7.91%), Lexin Medical (-7.26%), and New Industry (-6.44%).

Industry news:

On January 2, the official website of the State Food and Drug Administration (NMPA) of China announced that the marketing applications for Lenaparvir tablets and lenaparvir injection, a Class 5.1 new drug declared by Gilead Sciences, have been approved. Lenacapavir is an HIV-1 capsid inhibitor, which has been approved for marketing in the European Union, the United States and other places for the treatment of adult patients with multidrug-resistant HIV infection in combination with other antiretroviral drugs.



Company news:

Puluo Pharmaceutical (000739): The company announced that its subsidiary Kangyu Pharmaceutical received the "Drug Clinical Trial Approval Notice" approved and issued by the State Food and Drug Administration, and the clinical trial application for semaglutide injection liquid remanagement and adult type 2 diabetes indications declared by Kangyu Pharmaceutical was approved.

Northgate (301333): The company announced that as of December 31, 2024, the company has repurchased a total of 1,442,000 shares of the company through centralized bidding transactions, accounting for about 1.49% of the company's current total share capital, with a total transaction amount of 56,062,734.00 yuan.

Baili Tianheng (688506): The company announced that the company's self-developed innovative biological drug BL-B01D1 for injection for patients with recurrent small cell lung cancer who have failed previous platinum-containing chemotherapy and anti-PD-1/PD-L1 monoclonal antibody therapy has been included in the breakthrough therapy list by the Center for Drug Evaluation of the National Medical Products Administration, and has recently been publicized.

Risk warning: the R&D and marketing of new drugs are less than expected; policy promotion exceeds expectations; Market competition intensifies the risk.